Emerging Diagnostic and Therapeutic Strategies for Tauopathies

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Neurology and Neuroscience Reports

• Publication date

  2017-08-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11910-017-0779-1PMID 28785992PMCID PMC5756477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy

  2017cited by this paper
• Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

  2017cited by this paper
• Which ante mortem clinical features predict progressive supranuclear palsy pathology?

  2017cited by this paper
• Amyloid β Plaque Reduction With Antibodies Crossing the Blood‐Brain Barrier, Which Was Opened in 3 Sessions of Focused Ultrasound in a Rabbit Model

  2017cited by this paper
• Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid

  2017cited by this paper
• Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.

  2017cited by this paper
• Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

  2017cited by this paper
• Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy

  2017cited by this paper
• Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

  2017cited by this paper
• Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration

  2017cited by this paper
• Ante mortem CSF tau levels correlate with post mortem tau pathology in FTLD (S49.001)

  2017cited by this paper
• Manual MRI morphometry in Parkinsonian syndromes

  2017cited by this paper
• L-Borneol induces transient opening of the blood–brain barrier and enhances the therapeutic effect of cisplatin

  2017cited by this paper
• 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy

  2017cited by this paper
• Subcortical 18 FAV-1451 Binding Patterns in Progressive Supranuclear Palsy

  2016cited by this paper
• Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.

  2016cited by this paper
• Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease

  2016cited by this paper
• Glutamate-Mediated Blood–Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery

  2016cited by this paper
• Deep clinical and neuropathological phenotyping of Pick disease

  2016cited by this paper
• Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy

  2016cited by this paper
• Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

  2016cited by this paper
• Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration

  2016cited by this paper
• Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

  2016cited by this paper
• Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.

  2016cited by this paper
• Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy.

  2016cited by this paper
• Explorer Validation of the new consensus criteria for the diagnosis of corticobasal degeneration

  2016cited by this paper
• CoQ10 in progressive supranuclear palsy

  2016cited by this paper
• Tau positron emission tomographic imaging in aging and early Alzheimer disease

  2016cited by this paper
• An autoradiographic evaluation of AV-1451 Tau PET in dementia

  2016cited by this paper
• Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration

  2016cited by this paper
• Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants

  2016cited by this paper
• Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome

  2016cited by this paper
• A new approach for a blood-brain barrier model based on phospholipid vesicles: Membrane development and siRNA-loaded nanoparticles permeability

  2016cited by this paper
• Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia

  2015cited by this paper
• A Phase II Trial of Tideglusib in Alzheimer's Disease

  2015cited by this paper
• Anti-tau antibody reduces insoluble tau and decreases brain atrophy

  2015cited by this paper
• PART is part of Alzheimer disease

  2015cited by this paper
• Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice

  2015cited by this paper
• Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy

  2015cited by this paper
• Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

  2015cited by this paper
• Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue

  2015cited by this paper
• Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase‐3β Signaling Pathway in an Alzheimer's Disease Model

  2015cited by this paper
• Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy

  2015cited by this paper
• Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

  2015cited by this paper
• Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine

  2015cited by this paper
• Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains

  2015cited by this paper
• Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.

  2015cited by this paper
• Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau.

  2015cited by this paper
• Tau immunotherapy for Alzheimer's disease.

  2015cited by this paper
• Valproic Acid Alleviates Memory Deficits and Attenuates Amyloid-β Deposition in Transgenic Mouse Model of Alzheimer’s Disease

  2015cited by this paper
• Tau Immunotherapy

  2015cited by this paper
• Low clinical diagnostic accuracy of early vs advanced Parkinson disease

  2014cited by this paper
• Primary age-related tauopathy (PART): a common pathology associated with human aging

  2014cited by this paper
• First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

  2014cited by this paper
• Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion.

  2014cited by this paper
• The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases

  2014cited by this paper
• Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein

  2014cited by this paper
• Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

  2014cited by this paper
• Tau silencing by siRNA in the P301S mouse model of tauopathy.

  2014cited by this paper
• Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

  2014cited by this paper
• Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies

  2014cited by this paper
• Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases

  2014cited by this paper
• Validation of the new consensus criteria for the diagnosis of corticobasal degeneration

  2014cited by this paper
• Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.

  2014cited by this paper
• Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist.

  2014cited by this paper
• Loss of MAP Function Leads to Hippocampal Synapse Loss and Deficits in the Morris Water Maze with Aging

  2014cited by this paper
• Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy for Tauopathies

  2014cited by this paper
• Motor and cognitive deficits in aged tau knockout mice in two background strains

  2014cited by this paper
• Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds

  2014cited by this paper
• A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

  2014cited by this paper
• Distinct tau prion strains propagate in cells and mice and define different tauopathies.

  2014cited by this paper
• Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

  2014cited by this paper
• Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

  2014cited by this paper
• p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.

  2014cited by this paper
• An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

  2013cited by this paper
• Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.

  2013cited by this paper
• White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration

  2013cited by this paper
• Dissociable effects of dopamine and serotonin on reversal learning.

  2013cited by this paper
• Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation*

  2013cited by this paper
• Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

  2013cited by this paper
• The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

  2013cited by this paper
• Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.

  2013cited by this paper
• Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP

  2013cited by this paper
• Specific Inhibition of p25/Cdk5 Activity by the Cdk5 Inhibitory Peptide Reduces Neurodegeneration In Vivo

  2013cited by this paper
• Globular glial tauopathies (GGT): consensus recommendations

  2013cited by this paper
• Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

  2013cited by this paper
• Criteria for the diagnosis of corticobasal degeneration

  2013cited by this paper
• Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin‐dependent kinase 5 activity in SH‐SY5Y neuroblastoma cells and primary neurons

  2013cited by this paper
• Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

  2013cited by this paper
• The midbrain to pons ratio

  2013cited by this paper
• Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

  2013cited by this paper
• Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy

  2013cited by this paper
• Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

  2013cited by this paper
• Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy

  2013cited by this paper
• Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA

  2013cited by this paper
• Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice.

  2013cited by this paper
• Brain homogenates from human tauopathies induce tau inclusions in mouse brain

  2013cited by this paper
• MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.

  2013cited by this paper
• Neurofibrillary tangle‐like tau pathology induced by synthetic tau fibrils in primary neurons over‐expressing mutant tau

  2013cited by this paper
• Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

  2013cited by this paper

• Tau-targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy.

  2025cites this paper
• Tau Oligomers in Alzheimer’s Disease: Modulation Effect of Osmolytes on Amplified Brain-Derived Tau Oligomers

  2025cites this paper
• Tau protein aggregation: A therapeutic target for neurodegenerative diseases.

  2025cites this paper
• Seeding Activity of Skin Misfolded Tau as a Biomarker for Tauopathies

  2024cites this paper
• Electromagnetic Radiation and Biophoton Emission in Neuronal Communication and Neurodegenerative Diseases.

  2024cites this paper
• Seeding activity of skin misfolded tau as a biomarker for tauopathies

  2024cites this paper
• The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies

  2023cites this paper
• Passive tau-based immunotherapy for tauopathies.

  2023cites this paper
• Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies

  2023cites this paper
• Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies

  2023cites this paper
• AAV-based gene therapy approaches for genetic forms of tauopathies and related neurogenetic disorders

  2022cites this paper
• Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy.

  2021cites this paper
• Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes

  2021cites this paper
• The Delayed Neuropathological Consequences of Traumatic Brain Injury in a Community-Based Sample

  2021cites this paper
• Dual-Phase β-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome

  2021cites this paper
• Current Status of Clinical Trials on Tau Immunotherapies

  2021cites this paper
• DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer’s, Related Tauopathies and Genetic Tauopathies

  2021cites this paper
• Distinct phosphorylation profiles of tau in brains of patients with different tauopathies.

  2021cites this paper
• High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

  2021cites this paper
• A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

  2021cites this paper
• Editorial: Back to the Future: On the Road Towards Precision Psychiatry

  2020cites this paper
• Tau immunotherapies: Lessons learned, current status and future considerations.

  2020cites this paper
• The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer’s Disease

  2020cites this paper
• Advances and Challenges in Understanding MicroRNA Function in Tauopathies: A Case Study of miR-132/212

  2020cites this paper
• Precision Medicine for Frontotemporal Dementia

  2019cites this paper
• Neuropathological Validation of Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases.

  2019cites this paper
• Disease-modifying therapies for tauopathies: agents in the pipeline

  2019influential citation
• The Role of Biomarkers in Alzheimer's Disease Drug Development.

  2019cites this paper
• Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration

  2018cites this paper
• Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

  2018cites this paper
• Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.

  2018cites this paper
• Ultrasonido focalizado de alta intensidad: alternativa para la cirugía funcional en los trastornos del movimiento

  2018cites this paper
• Novel monoclonal antibodies targeting the microtubule-binding domain of human tau

  2018cites this paper
• Structural Basis of Small Molecule Targetability of Monomeric Tau Protein.

  2018cites this paper
• Update on tauopathies

  2017cites this paper
• Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome

  2016cites this paper